A Smart Polyhydroxyalkanoate-Hyaluronic Acid Hybrid Biphasic Delivery Platform for Enhanced Alzheimer’s Symptom Management via Sustained Huperzine A Release

    May 2026 in “ European Cells and Materials ”
    Jianfei Wu, Yanwen Zhou, Yu Liu, Yu Yang, Yuandong Tang, Youguo Tan, Duanfang Cai, Kezhi Liu, Daixu Wei
    TLDR The new delivery system improves Alzheimer's symptoms by releasing Huperzine A slowly and effectively.
    The study presents a novel hyaluronic acid-based biphasic delivery platform for Huperzine A (HupA), aimed at improving Alzheimer's disease management. This system encapsulates HupA-loaded polyhydroxyalkanoate nanoparticles within a HA gel matrix, achieving complete drug encapsulation and extending HupA release for over 20 days. In vivo tests on AD mice showed significant therapeutic efficacy, including reduced amyloid-beta deposition, restored cholinergic function, suppressed glial activation, reduced neuroinflammation, enhanced neuronal survival, and preserved synaptic integrity. These effects led to improved spatial memory and reduced anxiety/depression-like behaviors. The study concludes that the HupA@(NP/Gel) system effectively addresses HupA delivery challenges, offering a promising strategy for Alzheimer's intervention.
    Discuss this study in the Community →